Will the 21st Century Cures Act further its aim to boost drug and device development in 2018? That’s one of the questions the life sciences industry and attorneys are asking for the new year.
Other issues to watch in 2018 include what the HHS and NIH will do to help fight the nation’s opioid epidemic. And in Congress, after a year of no action, there is still plenty of talk about prescription drug prices.
Bloomberg Law’s 2018 Outlook on Pharmaceutical & Life Sciences Law and Policy examines these issues and others that will have a significant impact on the industry in the coming year. The insights and commentary from industry leaders, legislators, and regulators, make this a must-read report.
The topics highlighted in the 2018 Outlook include:
- Pharmaceuticals and drug pricing, such as FDA’s plans to bring more competition to the market
- Patents issues and the CRISPR legal battle
- Medical research and the status of the Common Rule revisions
- Medical devices and the regulation of laboratory-developed tests
Download this report now for Bloomberg Law’s detailed look at what 2018 brings for pharma/life sciences policy.